This trial will test whether RIC is a tolerable and effective treatment for patients with cognitive impairment due to cerebral small vessel disease.
- Vascular Cognitive Impairment
- Cerebral Small Vessel Disease
- Vascular Dementia
1 Primary · 11 Secondary · Reporting Duration: 30 days and 90 days
Awards & Highlights
2 Treatment Groups
RIC once per day
1 of 2
RIC twice per day
1 of 2
24 Total Participants · 2 Treatment Groups
Primary Treatment: RIC once per day · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 60 - 85 · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- Ganesh, Aravind, Philip Barber, Sandra E Black, Dale Corbett, Thalia S Field, Richard Frayne, Vladimir Hachinski, et al.. 2020. “Trial of Remote Ischaemic Preconditioning in Vascular Cognitive Impairment (TRIC-VCI): Protocol”. BMJ Open. BMJ. doi:10.1136/bmjopen-2020-040466.
- 2019. "Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04109963.
Frequently Asked Questions
Does this trial currently have any available openings for participants?
"Per the information on clinicaltrials.gov, this research trial is actively seeking participants. The study was made public on September 26th 2019 and its details were recently updated June 7th 2022." - Anonymous Online Contributor
What is the current size of the cohort engaging in this research?
"Affirmative - the online data hosted on clinicaltrials.gov demonstrates that this medical trial is currently enrolling, with its first posting being dated September 26th 2019 and last updated June 7th 2022. Qualified candidates are sought from 1 centre for a total of 24 patients." - Anonymous Online Contributor
Is participation in this trial available for individuals?
"This medical trial is seeking 24 seniors between the ages of 60 and 85 with cerebral small vessel diseases. In order to qualify, participants must demonstrate independence in completing basic activities of daily living (responding positively to questions 2, 4, 5, 6, 7 8 9 and 14 on Bristol ADL scale), have visible evidence of CSVD on MRI or CT scans such as confluent white matter hypodensities/hyperintensities (ARWMC Scale) or two+ supratentorial infarcts; score <25 on Montreal Cognitive Assessment Test; exhibiting a noticeable decline from their previous cognitive functioning level according to patients" - Anonymous Online Contributor
Is the sample population of this research encompassing individuals aged sixty and above?
"The requirements for participation in this clinical trial mandate that applicants must fall within the age range of 60 to 85 years old. 57 trials are available for minors, and 937 studies offer enrollment opportunities to seniors." - Anonymous Online Contributor
Has the FDA sanctioned twice-daily administration of RIC?
"Our team has awarded RIC twice per day a rating of 2 due to the Phase 2 trial status, meaning there is sufficient evidence for safety but insufficient data on efficacy." - Anonymous Online Contributor